NICE does not recommend tucatinib for advanced breast cancer
NICE has published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.
Source: NHS Networks - Category: UK Health Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Herceptin | National Institute for Health and Clinical Excelle | UK Health | Xeloda